Cargando…

Exploring the immune-checkpoint inhibitors’ efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease

The advent of immune-checkpoint inhibitors targeting the programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) axis, both as monotherapy and in combination strategies, produced a paradigm change of the treatment algorithm for metastatic, non-oncogene addicted, non-small cell lung cancer (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passiglia, Francesco, Cetoretta, Valeria, De Filippis, Marco, Napoli, Valerio, Novello, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Review Article on Immunotherapy in Other Thoracic Malignancies and Uncommon Populations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8264339/ https://www.ncbi.nlm.nih.gov/pubmed/34295686 http://dx.doi.org/10.21037/tlcr-20-635

Ejemplares similares

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review
por: Naltet, Charles, et al.
Publicado: (2021)

Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?
por: Hendriks, Lizza E. L., et al.
Publicado: (2021)

Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
por: Guaitoli, Giorgia, et al.
Publicado: (2021)

Immunotherapy in other thoracic malignancies and uncommon populations
por: Remon, Jordi, et al.
Publicado: (2021)

Immune-Checkpoint Inhibitors Combinations in Metastatic NSCLC: New Options on the Horizon?
por: Passiglia, Francesco, et al.
Publicado: (2021)

Narrative review of immunotherapy in thymic malignancies
por: Benitez, Jose Carlos, et al.
Publicado: (2021)

First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Immunotherapy in malignant pleural mesothelioma: a review of literature data
por: Menis, Jessica, et al.
Publicado: (2021)

Immunotherapy in small cell lung cancer: one step at a time: a narrative review
por: Dumoulin, Daphne W., et al.
Publicado: (2021)

Current and future biomarkers for outcomes with immunotherapy in non-small cell lung cancer
por: Duchemann, Boris, et al.
Publicado: (2021)

Novel patterns of progression upon immunotherapy in other thoracic malignancies and uncommon populations
por: Ferrara, Roberto, et al.
Publicado: (2021)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022)

Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
por: Thompson, Jeffrey C, et al.
Publicado: (2020)

Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
por: So, WeiQing Venus, et al.
Publicado: (2023)

hMENA isoforms regulate cancer intrinsic type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC
por: Trono, Paola, et al.
Publicado: (2023)

Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
por: Huang, Richard S P, et al.
Publicado: (2023)

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
por: Maslov, Diana V, et al.
Publicado: (2021)

IMMU-01. IMMUNE CHECKPOINT INHIBITION FOR PEDIATRIC CNS TUMORS: A SINGLE INSTITUTION EXPERIENCE
por: Cacciotti, Chantel, et al.
Publicado: (2020)

IMMU-14. IMMUNE CHECKPOINT INHIBITOR THERAPY FOR TREATMENT OF SYNCHRONOUS CANCERS IN PAEDIATRIC PATIENTS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY
por: Henderson, Jacob, et al.
Publicado: (2020)

Risk factors and immunomodulators use in steroid-refractory checkpoint inhibitor pneumonitis
por: Li, Yanlin, et al.
Publicado: (2023)

IMMU-18. FAVORABLE OUTCOME IN REPLICATION REPAIR DEFICIENT HYPERMUTANT BRAIN TUMORS TO IMMUNE CHECKPOINT INHIBITION: AN INTERNATIONAL RRD CONSORTIUM REGISTRY STUDY
por: Bouffet, Eric, et al.
Publicado: (2020)

Editorial of special focus on melanoma immunotherapy
por: Rossi, Ernesto
Publicado: (2022)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

IMMU-07. Interim analysis of the HIT-HGG Rez Immunvac study - Dendritic cell vaccination with partial T(reg) depletion and double checkpoint blockade in children with relapsed high-grade gliomas.
por: Eyrich, Matthias, et al.
Publicado: (2022)

Combining radiotherapy with targeted therapies in non-small cell lung cancer: focus on anti-EGFR, anti-ALK and anti-angiogenic agents
por: Wrona, Anna, et al.
Publicado: (2021)

Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC
por: Keegan, Alissa, et al.
Publicado: (2020)

Challenges in synergizing radiotherapy with immunotherapy to unlock the abscopal effect in metastatic NSCLC: A systematic review
por: Liu, Jason, et al.
Publicado: (2023)

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
por: Beattie, Jason, et al.
Publicado: (2021)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Radiotherapy in thoracic malignancies: the preface
por: Jassem, Jacek, et al.
Publicado: (2021)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

CD8(+) TILs in NSCLC differentiate into TEMRA via a bifurcated trajectory: deciphering immunogenicity of tumor antigens
por: Lee, Sung-Woo, et al.
Publicado: (2021)

Experiences of allogeneic hematopoietic cell transplantation following non-myeloablative conditioning regimen in severely comorbid patients with myelofibrosis: case series with a patient presenting with extensive extramedullary hematopoiesis
por: Yoon, Jae-Ho, et al.
Publicado: (2020)

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
por: Jiang, Xiaoyu, et al.
Publicado: (2020)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma
por: Bersanelli, Melissa, et al.
Publicado: (2023)

Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis
por: Sise, Meghan E, et al.
Publicado: (2023)

Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
por: Spillane, Susan, et al.
Publicado: (2020)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a7c38pcjt0tva2icjikldknnjj